

Client: Example Client ABC123 123 Test Drive Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

## **Patient: Patient, Example**

Unknown
Male
01234567890ABCD, 012345
01234567890ABCD
00/00/0000 00:00

## Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication with Reflex to Sequencing ARUP test code 2011241

Duchenne/Becker MD (DMD) Reflex Specimen whole Blood

Duchenne/Becker MD (DMD) DelDup MLPA	Negative
Duchenne/Becker MD (DMD) Reflex Interp	Negative RESULT No pathogenic variants were detected in the DMD gene.
	INTERPRETATION No pathogenic variants were detected in the DMD gene. This result decreases the likelihood of, but does not exclude, a diagnosis of Duchenne/Becker muscular dystrophy. Please refer to the background information included in this report for the methodology and limitations of this test.
	RECOMMENDATIONS Medical screening and management should rely on clinical findings and family history. If this individual has a family history, determination of a causative familial variant in an affected family member is necessary for optimal interpretation of this negative result. Further testing may be warranted if there is a familial variant that is not detectable by this assay. Genetic consultation is recommended.
	COMMENTS Likely benign and benign variants are not reported. Variants in the following region(s) may not be detected by NGS with sufficient confidence in this sample due to technical limitations: None
	This result has been reviewed and approved by

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruptab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director



BACKGROUND INFORMATION: Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication with Reflex to Sequencing

CHARACTERISTICS: Symptoms of Duchenne muscular dystrophy (DMD) usually begin in childhood and include fatigue, learning difficulties, muscle weakness, progressive difficulty walking with eventual wheelchair dependency, breathing difficulties and heart disease. Symptoms of Becker muscular dystrophy (BMD) are similar to DMD but begin at a later age and progress at a slower rate. Dilated cardiomyopathy has been observed in nearly all affected males and many female carriers of DMD and BMD.

EPIDEMIOLOGY: Incidence of DMD is 1 in 3,500 male births; Incidence of BMD is 1 in 19,000 male births.

INHERITANCE: X-linked; de novo variants occur in one-third of cases.

PENETRANCE: Males: 100 percent Females: Varies with X-chromosome inactivation

CLINICAL SENSITIVITY: Approximately 95 percent.

METHODOLOGY: Multiplex ligation-dependent probe amplification (MLPA) of the DMD gene. If results were negative or inconclusive, testing was reflexed to targeted capture of all coding exons and exon-intron junctions of the DMD gene, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and confirm reported variants. Human genome build 19 (Hg 19) was used for data analysis.

ANALYTICAL SENSITIVITY: The analytical sensitivity for MLPA is greater than 99 percent. The analytical sensitivity for sequencing is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions from 1-10 base pairs in size. Variants greater than 10 base pairs may be detected by sequencing, but the analytical sensitivity may be reduced.

LIMITATIONS: A negative result does not exclude a heritable form of muscular dystrophy. This test only detects variants within the coding regions and intron-exon boundaries of the DMD gene. Regulatory region variants and deep intronic variants will not be identified and breakpoints of large deletions/duplications will not be determined. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions. This assay may not detect low-level somatic variants associated with disease. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Non-coding transcripts were not analyzed.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

H=High, L=Low, \*=Abnormal, C=Critical

Inless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruptab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 24-122-123821 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 2 of 3 | Printed: 5/8/2024 3:10:13 PM 4848



VERIFIED/REPORTED DATES						
Procedure	Accession	Collected	Received	Verified/Reported		
Duchenne/Becker MD (DMD) Reflex Specimen	24-122-123821	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		
Duchenne/Becker MD (DMD) DelDup MLPA	24-122-123821	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		
Duchenne/Becker MD (DMD) Reflex Interp	24-122-123821	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00		

## END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com 500 Chipeta Way, Salt Lake City, UT 84108-1221 Jonathan R. Genzen, MD, PhD, Laboratory Director Patient: Patient, Example ARUP Accession: 24-122-123821 Patient Identifiers: 01234567890ABCD, 012345 Visit Number (FIN): 01234567890ABCD Page 3 of 3 | Printed: 5/8/2024 3:10:13 PM 4848